NV.gov
Healthcare Facility TB Screening Manual
Technical Bulletins
- Sputum Specimens for TB NAAT Testing by NSPHL, 2/2025
- TB Pyrazinamide Susceptibility Testing Suspended 9/2024
- LTBI Reporting Regulations Requirements
- Concerning Trends of TB Nevada, 2023
- Concerning TB Trends and Guidance for Health Care Providers
- TB NAAT MTB/Rif Rifampin Detected Reporting, 2-2023
- Rapid NAA Tests for MTB Detection, 4-2022
- TB Testing During COVID-19 Vaccinations, Updated 9-2021
- Health Care Personnel Updated TB Screening Recommendations 7-2019
- Latent TB Infection (LTBI) 12-Dose Treatment Regimen 12/2018
- Tuberculosis Technical Instructions for Civil Surgeons
- The Use of QuantiFERON vs TST 2-2008
Nevada TB Manual
- Chapter 1 Introduction
- Chapter 2 Infection Control, Rev. 3-2020
- Chapter 3 Diagnosis of TB Disease
- Chapter 4 Treatment of TB Disease
- Chapter 5 Diagnosis of LTBI
- Chapter 6 Treatment of LTBI, Rev. 3-2020
- Chapter 7 Case Management
- Chapter 8 Contact Investigations
- Chapter 10 Surveillance (and Reporting)
- Chapter 11 Targeted Testing for LTBI
- Chapter 12 Pediatric TB and LTBI, Rev. 3-2020
- Chapter 13 Patient Education
- Chapter 14 TB Confidentiality
Nevada TB Policies and Resources
CDC Reports
- Guidelines for Treatment of LTBI, updated Feb 2020
- Report of Tuberculosis in the U.S., 2018
- Guidelines for TB Testing Activities in Healthcare Personnel, 2019
- Guidelines for Prevention of TB Transmission in Healthcare Facilities, 2005
- Guidelines for Preventing the Transmission of Mtb in Healthcare Settings FAQ's
- Controlling Tuberculosis in the U.S.
- Prevention and Control of Tuberculosis in Detentional Facilities